Treatment and Pathophysiology of Pulmonary Hypertension

Patients with various forms of PH are cared for and actively involved in research projects within the framework of the Department of Pulmonology's focus on pulmonary hypertension (PH). We are are especially interested in the pathophysiological mechanisms that cause pulmonary hypertension and whether we can use certain therapies to limit the spread of the disease. Of particular interest is the cause of low blood oxygen in connection with PH; at night, during exercise and at high altitudes.

We are currently investigating the direct effect of oxygen therapy on performance during bicycle tests, on long-term endurance, as well as on oxygen levels in the brain and muscle tissues. Other research projects of ours are concerned with quality of life and the long-term course of the disease, while we also conduct clinical trials in collaboration with the pharmaceutical industry.

Current projects

TitleEthical approval numberClinical Trial Registration
​The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension
​2016-00146
​Acute hemodynamic and chronic clinical effects of acetazolamide in pulmonary hypertension
​2016-00089
Zurich Pulmonary Hypertension Outcome Assessment Cohort2014-0214
​Effect of exercise training in patients with pulmonary hypertension
​2015-0231
​Acute response to hypoxia in patients with precapillary hypertension
2018-00455
A multi-center, double-blind, placebo-controlled, phase 4 study in patients with pulmonary arterial hypertension to assess the effect of Selexipag on daily life physical activity and patient's self-reported symptoms and their impacts
2017-01274
​The effect of commercial air travel on patients suffering from pulmonary hypertension-a prospective, metacentric analysis
​2017-00560
​A prospective, randomized, international, multicenter, double-arm, controlled, open-label study of Riociguat in patients with pulmonary arterial hypertension (PAH) who are on a stable does of PDE-5i with or without ERA, but not at treatment goal
2017-00035
Randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the hemodynamic effects of Riociguat (BAY 63-2521) as well as safety and kinetics in patients with pulmonary hypertension associated with left ventricular
2010-0224
​Post-authorization safety study (PASS): observational cohort study of PAH patients newly treated with either Uptravi (selexipag) or any other PAH-specific therapy, in clinical practice
​2018-00386
​Pulmonary Hemodynamics during Exercise - Research Network (PEX-NET)
​2019-00075



Information

Tel +41 44 255 22 20
Fax +41 44 255 85 17
pulmonalehypertonie@usz.ch

Team

Professor Silvia Ulrich, MD, Senior Attending Physician
Mona Lichtblau, MD, Attending Physician
Charlotte Berlier, MD, Attending Physician

Stéphanie Saxer, MSc, Research Assistant
Simon Schneider, BSc, Research Assistant
Simone Stickel, Study Nurse
Claudia Thalmann, Study Nurse
Christoph Jansen, Study Nurse
Mirjam Brenzikofer, Study Nurse
Isabel Schmied, Secretary
Conny Cajet, Secretary

Contact address

Department of Pulmonology
Professor Silvia Ulrich, MD
University Hospital Zurich
Rämistrasse 100
8091 Zurich

Last update: 13.01.2020 | Person responsible:
Prof Silvia Ulrich, MD

We use cookies to make our website user-friendly, to continuously improve it and to analyze the traffic of our website. By continuing to browse the site, you are agreeing to our use of cookies. Further information can be found in our privacy policy.